OPINION: The war for insulin affordability isn't over yet
I was distributing newspapers on the morning of March 1, 2023, when my earbuds suddenly paused my Taylor Swift playlist to bombard me with a breaking news alert: Eli Lilly, one of the biggest insulin producers in the world, had decided to cap their out-of-pocket prices at $35 a month. I was standing in the middle of Global Commons, holding dozens of papers, when I broke down in tears at the sight of my phone. At that moment, an NBC news alert changed the trajectory of my life and informed me I could now afford to pursue my dreams.